Crcm LP Has $91.78 Million Position in GRAIL, Inc. $GRAL

Crcm LP trimmed its position in GRAIL, Inc. (NASDAQ:GRAL) by 41.8% in the 4th quarter, Holdings Channel reports. The firm owned 1,072,374 shares of the company’s stock after selling 770,277 shares during the quarter. GRAIL accounts for 31.0% of Crcm LP’s holdings, making the stock its largest position. Crcm LP’s holdings in GRAIL were worth $91,784,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. N.E.W. Advisory Services LLC bought a new position in GRAIL in the 4th quarter valued at $26,000. Comerica Bank boosted its holdings in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Elyxium Wealth LLC bought a new position in GRAIL in the 4th quarter valued at $31,000. Intesa Sanpaolo S.p.A. bought a new position in GRAIL in the 4th quarter valued at $44,000. Finally, Ankerstar Wealth LLC bought a new position in GRAIL in the 4th quarter valued at $45,000.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GRAL shares. Mizuho started coverage on shares of GRAIL in a research report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective on the stock. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. TD Cowen raised their price objective on shares of GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley lowered their price objective on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $67.00.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: Multiple law firms announced or reiterated class-action lawsuits and securities-fraud investigations against GRAIL, citing alleged violations of federal securities laws and encouraging affected shareholders to seek lead-plaintiff status by the August 4, 2026 deadline. Article: GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law
• Negative Sentiment: Several notices specifically link the litigation to GRAIL’s February 19 disclosure that the primary endpoint of a study or trial was not met, which investors say triggered a major selloff and damaged confidence in the company’s outlook. Article: Securities Fraud Investigation Into Grail, Inc. (GRAL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
• Negative Sentiment: Law firms are warning investors about class-action deadlines and urging those with losses in GRAIL stock to participate, adding to headline risk and keeping legal overhang front and center for the shares. Article: GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Insider Buying and Selling at GRAIL

In related news, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares in the company, valued at $13,012,596.48. This trade represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the completion of the transaction, the chief executive officer owned 518,582 shares in the company, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 232,464 shares of company stock worth $11,621,242 in the last 90 days. 1.83% of the stock is owned by company insiders.

GRAIL Stock Down 0.5%

Shares of NASDAQ:GRAL opened at $59.85 on Friday. The stock has a market cap of $2.57 billion, a PE ratio of -5.77 and a beta of 3.15. The company’s fifty day moving average is $58.23 and its 200 day moving average is $74.56. GRAIL, Inc. has a 52 week low of $29.95 and a 52 week high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. The company had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. Sell-side analysts anticipate that GRAIL, Inc. will post -10.99 EPS for the current year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.